09:45 AM EST - Knight Therapeutics Inc. : Announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America. Knight Therapeutics Inc.
shares T.GUD are trading unchanged at $5.31.
